Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Oropharyngeal Neoplasms 7Mouth Neoplasms 7Laryngeal Neoplasms 7Carcinoma 6Hypopharyngeal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Paranasal Sinus Neoplasms 2Lymphoid Interstitial Pneumonia 2Cholangiocarcinoma 2Anus Neoplasms 2Adenocarcinoma of Lung 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomatitis 1Stomach Neoplasms 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1Sertoli-Leydig Cell Tumor 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

University of Washington

Phase 2 Completed
17 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Mayo Clinic

Phase 2 Completed
2 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡